- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.02. | Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal | ||
| 18.02. | FDA accepts filing for Moderna flu vaccine after swift rethink | ||
| 18.02. | Preclinical eye disease biotech sets sights on $17M NYSE IPO | ||
| 18.02. | Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study | ||
| 17.02. | Boehringer axes inhaled gene therapy after viewing cystic fibrosis data | ||
| 17.02. | Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering | ||
| 17.02. | Cyrano noses toward pivotal trial after midphase smell loss win | ||
| 17.02. | Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push | ||
| 17.02. | Sanofi points to 'key opportunity' for Teva-partnered IBD in long-term data | ||
| 13.02. | FDA rejects Disc's rare disease drug despite commissioner's voucher | ||
| 13.02. | 'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments | ||
| 13.02. | After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio | ||
| 13.02. | Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg | ||
| 13.02. | Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans | ||
| 12.02. | Lundbeck's migraine prevention treatment sees ph. 2 success after trial's earlier setback | ||
| 12.02. | Seres to lay off 30% of employees, pause lead program in latest strategic shift | ||
| 12.02. | BridgeBio preps approval push after dwarfism drug increases children's height in phase 3 | ||
| 11.02. | Takeda downsizes Boston footprint amid consolidation effort | ||
| 11.02. | After facing Moderna's ire, FDA stands behind decision to spurn mRNA flu filing | ||
| 11.02. | Madrigal pens $4.4B deal for Ribo's preclinical siRNA programs in latest Rezdiffra MASH play | ||
| 11.02. | Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario | ||
| 10.02. | Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data | ||
| 10.02. | AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data | ||
| 10.02. | Evommune's Dupixent-like phase 2 eczema data drive 75% stock rally | ||
| 10.02. | AstraZeneca relaxed about relaxin drug's poor efficacy in phase 2 heart failure trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.